Publication BLAZE-1 - Chen P, N Engl J Med (2020) (published paper)
Dates: 2020-06-17 to 2020-08-21
Funding: Private (Eli Lilly)
Conflict of interest: Yes
Multicenter / USA
Follow-up duration (days): 29
700/2800/7000mg arms merged, IV, once off for 1 hour.
|Characteristics of participants
Mean age : NR
Severity : Mild: n= 452/ Asymptomatic: n=0
Number of vaccinated participants: NR
|In the register
Change from Baseline to Day 11 in SARS-CoV-2 Viral Load
|In the report
Change from baseline in the SARS-CoV-2 viral load at day 11 (±4 days) after positive results on testing.
Yes. In English
Data-sharing willing stated in the publication:
|Risk of bias
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review
In addition to the published article, the trial registry, protocol, statistical plan, supplementary materials and response from contact with authors were used in data extraction and assessment of risk of bias. The published report was a preplanned interim analysis of patients randomized to receive one of three doses of LY-CoV555 (also known as LY3819253) and placebo. The pre-stated sample sizes for these arms were reached. Additional arms in which patients are randomized to receive and combination of LY3819253 and LY3832479 are ongoing. There were some differences in the outcomes included in the trial registry and protocol and the published article. There were no differences in study treatments.
This study was updated on December 29th with data received from contact with authors. The study was updated by Gotleib 2021 for all outcomes except hospitalization or death. We consider Gotleib as the updated report except for the outcome hospitalization or death that will be collected from this study.